<DOC>
	<DOCNO>NCT02075268</DOCNO>
	<brief_summary>An open label , parallel study characterize pharmacokinetics pharmacodynamics Prasugrel 30 mg 60 mg healthy male adult subject</brief_summary>
	<brief_title>Clinical Trial Characterize Pharmacokinetic-pharmacodynamic ( PKPD ) Prasugrel 10 mg 30 mg Healthy Volunteers</brief_title>
	<detailed_description>1 . Screening 2 . Enrollment treatment randomization 3 . Confinement Research Unit day - 1 day 2 4 . Outpatient visit : 2 time ( 48 73 hour dose ) 5 . Drug administration : Overnight Fasting 6 . Blood sample PK , PD genotyping 1 . PK : 24 hour dose 2 . PD : 72 hour dose</detailed_description>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>male age 19 45 year weigh 60 kg body mass index 18 30 kg/m2 history state clinically significant disease gastrointestinal disease may interfere absorption drug history hypersensitivity prasugrel drug history take herbal medication within 30 day dose take prescription medication within 14 day dose take counter drug within 7 day dose take investigational drug within 60 day dose transfuse within 30 day donate blood within 60 day dose Positive serology test ( Hepatitis B surface antigen ( HBs Ag ) , HIV , HCV ) Clinically significant find laboratory result electrocardiogram result</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Korean</keyword>
	<keyword>Healthy</keyword>
	<keyword>Male</keyword>
</DOC>